Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
AnaptysBio, Inc. director John A. Orwin reported new equity awards on a Form 4. On January 6, 2026, he was granted a stock option covering 8,250 shares of common stock with an exercise price of $43.91 per share. This option vests in equal monthly installments of 1/12 of the total shares starting on February 6, 2026, as long as he continues providing service to the company on each vesting date.
On the same date, he also received 6,000 restricted stock units (RSUs), each representing the right to receive one share of common stock for no cash consideration. These RSUs vest as to 100% of the total units on the date of AnaptysBio’s 2027 annual meeting of shareholders, subject to his continued service. Both the option and RSUs are reported as held directly.
Eric J. Loumeau filed a Form 144 notice covering a planned sale of 7,622 shares of ANAB common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $348,212.59. The shares are part of restricted stock awards acquired on January 3, 2025 (4,294 shares) and January 6, 2025 (3,328 shares), both from the issuer.
Over the prior three months, the notice lists multiple sales of ANAB common stock by Loumeau, including 10,000 shares sold on December 17, 2025 for $460,000.00, another 10,000 shares on December 22, 2025 for $510,000.00, and 12,500 shares on December 16, 2025 for $560,800.25, plus smaller transactions. The form also includes a representation that the seller does not know of undisclosed material adverse information about ANAB.
AnaptysBio, Inc. President and CEO Daniel Faga reported equity transactions in a Form 4. On January 3, 2026, 34,677 restricted stock units (RSUs) were converted into the same number of shares of common stock at an exercise price of $0, reflecting RSU vesting. Each RSU represents a right to receive 1 share of common stock upon settlement for no consideration.
On January 5, 2026, Faga sold 15,309 shares of common stock at $43.26 per share. According to the footnote, this sale was made solely to cover tax withholding obligations through a “sell to cover” transaction and did not represent a discretionary sale. After these transactions, Faga directly beneficially owned 458,139 shares of common stock and 69,355 RSUs.
AnaptysBio, Inc. chief financial officer Dennis Mulroy reported the vesting of 8,292 restricted stock units on January 3, 2026, which converted into the same number of common shares at no cost upon settlement. Following this, his directly held common stock position increased to 17,693 shares.
On January 5, 2026, he sold 3,363 shares of AnaptysBio common stock at a price of $43.26 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After the sale, he directly held 14,330 shares of common stock and 16,585 RSUs, which continue to vest in 25% annual installments beginning January 3, 2025, subject to continued service.
AnaptysBio Chief Medical Officer Paul F. Lizzul reported routine equity activity involving vested RSUs and a related share sale. On January 3, 2026, 10,555 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held common stock to 37,522 shares. Each RSU represents the right to receive 1 share of common stock for no cash consideration.
On January 5, 2026, he sold 4,219 shares of common stock at $43.26 per share, leaving him with 33,303 directly owned shares. According to the disclosure, this sale was executed solely to cover tax withholding obligations from the RSU vesting through a "sell to cover" transaction and is described as not a discretionary transaction. The RSUs vest 25% annually starting January 3, 2025, subject to his continued service.
AnaptysBio insider files to sell common stock under Rule 144. A holder plans to sell 4,219 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/05/2026 on NASDAQ, with an aggregate market value of $189,644.05. The filing notes 28,023,368 shares of the issuer’s common stock outstanding, providing a baseline for the company’s share count. The shares to be sold were acquired as restricted stock units from the issuer on 01/05/2026, with payment listed as cash on the same date.
The form also reports that Paul F. Lizzul sold 1,500 common shares on 12/22/2025 for gross proceeds of $75,000 during the prior three months. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
AnaptysBio chief legal officer Eric Loumeau reported RSU vesting and a related share sale. On January 3, 2026, 7,287 restricted stock units converted into an equal number of AnaptysBio common shares at an exercise price of $0, reflecting previously granted equity that vested. The RSUs vest 25% per year starting on January 3, 2025, as long as he continues providing services to the company.
On January 5, 2026, Loumeau sold 2,983 common shares at $43.26 per share. According to the disclosure, this sale was a “sell to cover” transaction used solely to satisfy tax withholding obligations tied to the RSU vesting and was not a discretionary trade. After these transactions, he held 13,251 AnaptysBio common shares directly and 14,575 RSUs representing additional potential shares upon future vesting.
An ANAB insider filed a Rule 144 notice to sell 2,983 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $134,085.85. The shares come from restricted stock units acquired and paid for in cash on 01/05/2026.
The notice also lists recent activity over the prior three months, where Eric J. Loumeau sold multiple blocks of common stock on various December 2025 dates, with individual transactions ranging up to 10,000 shares and gross proceeds in the hundreds of thousands of dollars. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.
AnaptysBio, Inc.'s Chief Medical Officer reported an equity transaction involving company stock. On 12/22/2025, the officer exercised 1,500 employee stock options at an exercise price of $18.50 per share and acquired the same number of common shares. On the same date, the officer sold 1,500 shares of common stock at a price of $50.00 per share. After these transactions, the officer directly owned 26,967 shares of AnaptysBio common stock and held 83,500 stock options from the reported grant.
The filing notes that the sale was made under a Rule 10b5-1 trading plan adopted on April 14, 2025, which is a pre-arranged plan for trading shares. It also states that the reported stock option is fully vested and that the officer holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which vest according to their terms.
AnaptysBio’s chief legal officer reported option exercises and share sales. On December 16–18, 2025, the officer exercised employee stock options to buy common stock at $14.02 and $20.16 per share, then sold portions of the resulting shares in several trades.
Sales were made under a pre-arranged Rule 10b5-1 trading plan, with weighted average sale prices including $44.6756, $45.2369 and $46.00 per share. After these transactions, the officer directly owned 8,947 shares of common stock and held fully vested options covering 53,000 shares, plus additional options to purchase up to 414,810 shares that vest according to their terms.